Last reviewed · How we verify
Augment with Memantine
Augment with Memantine is a combination of a glutamate receptor antagonist and a NMDA receptor antagonist, which may help to improve cognitive function in patients with Alzheimer's disease.
Augment with Memantine is a combination of a glutamate receptor antagonist and a NMDA receptor antagonist, which may help to improve cognitive function in patients with Alzheimer's disease. Used for Moderate to severe Alzheimer's disease.
At a glance
| Generic name | Augment with Memantine |
|---|---|
| Sponsor | Shanghai Mental Health Center |
| Drug class | NMDA receptor antagonist |
| Target | NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
Memantine, a NMDA receptor antagonist, works by blocking the action of glutamate, a neurotransmitter that can be toxic to brain cells in high amounts. Augment, the other component, is not well-documented, but it may enhance the effects of memantine or provide additional benefits.
Approved indications
- Moderate to severe Alzheimer's disease
Common side effects
- Dizziness
- Headache
- Confusion
- Fatigue
- Nausea
Key clinical trials
- Pattern Separation in Major Depressive Disorder (PHASE1)
- Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases (PHASE3)
- Treatment of Orthostatic Intolerance (PHASE1, PHASE2)
- Pragmatic Trial of Obsessive-compulsive Disorder (PHASE2)
- Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis (PHASE1)
- Memantine Hydrochloride for Treatment of Cognitive Dysfunction Due to Traumatic Brain Injury (PHASE3)
- The Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease (NA)
- An Open-Label Trial of Memantine for Cognitive Impairment in Patients With Post-Traumatic Stress Disorder (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Augment with Memantine CI brief — competitive landscape report
- Augment with Memantine updates RSS · CI watch RSS
- Shanghai Mental Health Center portfolio CI